Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Suhyun Park , Sang Hyoung Park
Correspondence to: Sang Hyoung Park
ORCID https://orcid.org/0000-0002-5366-5749
E-mail shpark78@amc.seoul.kr
See “Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study” by Hong Yang, et al. on page 726, Vol. 16, No. 5, 2022.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2022;16(5):663-664. https://doi.org/10.5009/gnl220364
Published online September 15, 2022, Published date September 15, 2022
Copyright © Gut and Liver.
The risk of opportunistic infections among patients with inflammatory bowel disease (IBD) is an emerging issue of safety that continues to evolve along with the emergence of new mechanisms of therapy and new approaches to treatment. It is an important safety issue, as immunomodulators and biologic agents are being used more often and earlier during the disease course.1 In particular, biologic therapies have been associated with an increased risk of opportunistic infections.2,3 Even though immunosuppressive therapy is a major risk of opportunistic infections in patients with IBD, some risk factors are inherent to individual patients’ characteristics such as malnutrition, older age, congenital immunodeficiency, human immunodeficiency virus infection, chronic diseases, and diabetes mellitus.4 Therefore, the European Consensus guidelines on the prevention, diagnosis, and management of opportunistic infections detail a vaccination and systemic workup to consider before the commencement of immunosuppressive therapy, including steroids, azathioprine, 6‐mercaptopurine, and biologic agents.4
In this issue of
Considering the different epidemiological perspectives of infection as well as the differences in resources between Asia and the West, there are gaps in approaches to diagnosis, treatment, and prevention of opportunistic infections in IBD. For example, due to the intermediate endemicity of hepatitis A and hepatitis B viruses in Korea compared with that in the United States and Western Europe, Park
Yang
Each of these findings should further motivate clinicians to strive to optimize the guidelines to be more suitable for Asian patients through the development of health facilities, adjustment of medical insurance policies, and increased vaccination efforts.
No potential conflict of interest relevant to this article was reported.
Gut and Liver 2022; 16(5): 663-664
Published online September 15, 2022 https://doi.org/10.5009/gnl220364
Copyright © Gut and Liver.
Suhyun Park , Sang Hyoung Park
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
Correspondence to:Sang Hyoung Park
ORCID https://orcid.org/0000-0002-5366-5749
E-mail shpark78@amc.seoul.kr
See “Current Status of Opportunistic Infection in Inflammatory Bowel Disease Patients in Asia: A Questionnaire-Based Multicenter Study” by Hong Yang, et al. on page 726, Vol. 16, No. 5, 2022.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
The risk of opportunistic infections among patients with inflammatory bowel disease (IBD) is an emerging issue of safety that continues to evolve along with the emergence of new mechanisms of therapy and new approaches to treatment. It is an important safety issue, as immunomodulators and biologic agents are being used more often and earlier during the disease course.1 In particular, biologic therapies have been associated with an increased risk of opportunistic infections.2,3 Even though immunosuppressive therapy is a major risk of opportunistic infections in patients with IBD, some risk factors are inherent to individual patients’ characteristics such as malnutrition, older age, congenital immunodeficiency, human immunodeficiency virus infection, chronic diseases, and diabetes mellitus.4 Therefore, the European Consensus guidelines on the prevention, diagnosis, and management of opportunistic infections detail a vaccination and systemic workup to consider before the commencement of immunosuppressive therapy, including steroids, azathioprine, 6‐mercaptopurine, and biologic agents.4
In this issue of
Considering the different epidemiological perspectives of infection as well as the differences in resources between Asia and the West, there are gaps in approaches to diagnosis, treatment, and prevention of opportunistic infections in IBD. For example, due to the intermediate endemicity of hepatitis A and hepatitis B viruses in Korea compared with that in the United States and Western Europe, Park
Yang
Each of these findings should further motivate clinicians to strive to optimize the guidelines to be more suitable for Asian patients through the development of health facilities, adjustment of medical insurance policies, and increased vaccination efforts.
No potential conflict of interest relevant to this article was reported.